- Home
- APLS
as 03-25-2025 4:00pm EST
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 3.3B | IPO Year: | 2017 |
| Target Price: | $45.53 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Buy | Number of Analysts: | 18 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.60 | EPS Growth: | N/A |
| 52 Week Low/High: | $23.37 - $59.91 | Next Earning Date: | 05-06-2025 |
| Revenue: | $781,367,000 | Revenue Growth: | 97.02% |
| Revenue Growth (this year): | 12.95% | Revenue Growth (next year): | 21.35% |
Stock Insider Trading Activity of Apellis Pharmaceuticals Inc. (APLS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Watson David O. | APLS | General Counsel | Mar 4 '25 | Sell | $25.10 | 5,569 | $139,789.14 | 138,730 | |
| DeLong Mark Jeffrey | APLS | Chief Business & Strat Officer | Feb 11 '25 | Sell | $28.54 | 363 | $10,359.58 | 83,945 | |
| Deschatelets Pascal | APLS | Chief Scientific Officer | Jan 29 '25 | Sell | $29.52 | 826 | $24,386.49 | 1,147,716 | |
| Nicholson Nur | APLS | Chief Technical Officer | Jan 29 '25 | Sell | $29.52 | 825 | $24,356.97 | 83,664 | |
| Sullivan Timothy Eugene | APLS | Chief Financial Officer | Jan 29 '25 | Sell | $29.52 | 546 | $16,119.89 | 128,665 | |
| Watson David O. | APLS | General Counsel | Jan 29 '25 | Sell | $29.52 | 695 | $20,518.90 | 138,730 | |
| Townsend Adam J. | APLS | Chief Commercial Officer | Jan 29 '25 | Sell | $29.52 | 695 | $20,518.90 | 84,050 | |
| Lewis Karen | APLS | Chief People Officer | Jan 29 '25 | Sell | $29.52 | 364 | $10,746.59 | 70,251 | |
| Francois Cedric | APLS | Chief Executive Officer | Jan 29 '25 | Sell | $29.52 | 2,824 | $83,374.65 | 415,695 | |
| Eisele Jeffrey | APLS | Chief Development Officer | Jan 29 '25 | Sell | $29.52 | 278 | $8,207.56 | 55,312 |
Latest Apellis Pharmaceuticals Inc. News
APLS Breaking Stock News: Dive into APLS Ticker-Specific Updates for Smart Investing
TipRanks
4 days ago
Morgan Stanley says Fabhalta’s label leaves opportunity for Apellis’ Empaveli
Benzinga
21 days ago
Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst
MT Newswires
21 days ago
UBS Adjusts Apellis Pharmaceuticals Price Target to $43 From $45, Maintains Buy Rating
Zacks
23 days ago
Apellis Q4 Loss Narrower Than Expected, Syfovre Sales Drive Revenues
MT Newswires
23 days ago
Wedbush Adjusts Price Target on Apellis Pharmaceuticals to $29 From $30, Keeps Neutral Rating
MT Newswires
23 days ago
RBC Trims Price Target on Apellis Pharmaceuticals to $25 From $26, Keeps Sector Perform Rating
Simply Wall St.
25 days ago
Apellis Pharmaceuticals Full Year 2024 Earnings: Beats Expectations
GuruFocus.com
25 days ago
Apellis Pharmaceuticals Inc (APLS) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and ...
Compare APLS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "APLS Apellis Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.